Vantictumab
- CAS No.
- 1345009-45-1
- Chemical Name:
- Vantictumab
- Synonyms
- Vantictumab;Vantictumab (anti-FZD);Research Grade Vantictumab;Research Grade Vantictumab (DHJ82501)
- CBNumber:
- CB88080888
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
| Product description | Number | Pack Size | Price |
| Vantictumab 99.00% | CS-0147830 | 1mg | $325 |
| Vantictumab 99.00% | CS-0147830 | 5mg | $845 |
| Vantictumab 99.00% | CS-0147830 | 10mg | $1354 |
| Vantictumab 99.00% | CS-0147830 | 1mg | $325 |
| Vantictumab 99.00% | CS-0147830 | 5mg | $845 |
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | 88WBI2D80S |
| NCI Drug Dictionary | vantictumab |
Vantictumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0147830 | Vantictumab 99.00% | 1345009-45-1 | 1mg | $325 | 2026-06-04 | Buy |
| ChemScene | CS-0147830 | Vantictumab 99.00% | 1345009-45-1 | 5mg | $845 | 2026-06-04 | Buy |
| ChemScene | CS-0147830 | Vantictumab 99.00% | 1345009-45-1 | 10mg | $1354 | 2026-06-04 | Buy |
| ChemScene | CS-0147830 | Vantictumab 99.00% | 1345009-45-1 | 1mg | $325 | 2026-06-04 | Buy |
| ChemScene | CS-0147830 | Vantictumab 99.00% | 1345009-45-1 | 5mg | $845 | 2026-06-04 | Buy |
Vantictumab Chemical Properties,Uses,Production
Uses
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab can be studied against cancers through direct actions on tumor cells, including CSCs, and effects on the stroma, such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma[1][2][3].
References
[1] Davis SL, et al. A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer. Invest New Drugs. 2020 Jun;38(3):821-830. DOI:10.1007/s10637-019-00824-1
[2] Diamond JR, et al. Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer. Breast Cancer Res Treat. 2020 Nov;184(1):53-62. DOI:10.1007/s10549-020-05817-w
[3] Smith D C, et al. Abstract B24: Biomarker analysis in the first-in-human phase 1a study for vantictumab (OMP-18R5; anti-Frizzled) demonstrates pharmacodynamic (PD) modulation of the Wnt pathway in patients with advanced solid tumors[J]. Molecular Cancer Therapeutics, 2013, 12(11_Supplement): B24-B24.
Vantictumab Preparation Products And Raw materials
Raw materials
Preparation Products
Vantictumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | +1-781-999-5354; +17819995354 | marketing@targetmol.com | United States | 32466 | 58 |
| Aladdin Scientific | tp@aladdinsci.com | United States | 57505 | 58 | |
| Shanghai YuanYe Biotechnology Co., Ltd. | 021-61312847; 18021002903 | 3008007409@qq.com | China | 89686 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1566 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10308 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24955 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9865 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7081 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11972 | 58 |
View Lastest Price from Vantictumab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-04-22 | Vantictumab
1345009-45-1
|
$247.00-987.00 | 99% (SDS-PAGE); 97.7% (SEC-HPLC) | 10g | TargetMol Chemicals Inc. |
-
- Vantictumab
1345009-45-1
- $247.00-987.00
- 99% (SDS-PAGE); 97.7% (SEC-HPLC)
- TargetMol Chemicals Inc.
